Results From THOR Study of Erdafitinib in FGFR-Altered Urothelial Cancer
November 7th 2023Arlene O. Siefker-Radtke, MD, discusses the results of the phase 3 THOR study of erdafitinib vs pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations.
Watch
EV-302: Impact of Enfortumab Vedotin + Pembrolizumab in Metastatic Bladder Cancer
November 7th 2023Shifting their focus to metastatic bladder cancer, the Oncology Brothers and Rana McKay, MD, reflect on data from EV-302 and consider how enfortumab vedotin + pembrolizumab has shifted the treatment landscape.
Watch
SunRISe-1: Updated Data With TAR-200 Monotherapy in NMIBC
November 7th 2023Key opinion leader Rana McKay, MD, joins the Oncology Brothers Rahul Gosain, MD, and Rohit Gosain, MD, to review updated data in GU cancer from ESMO 2023, starting with TAR-200 monotherapy in patients with NMIBC and the SunRISE-1 trial.
Watch
Phase 2 Study Tests Cabo/Nivo/Ipi in RCCvh
November 6th 2023Bradley McGregor, MD, discusses the rationale behind the multi-institutional, prospective, single-arm phase 2 trial of cabozantinib, nivolumab, and ipilimumab for the treatment of patients with renal cell carcinoma with variant histologies.
Watch
Bhatt Recaps Trial of Ruxolitinib in Steroid Refractory Sclerotic cGVHD
November 4th 2023Vijaya Raj Bhatt, MBBS, MS, discusses background and findings from a multicenter, phase 2 study of ruxolitinib for the treatment of patients with steroid refractory sclerotic chronic graft-versus-host disease.
Watch
Results and Key Takeaways From the TriMM-2 Study in Patients With RRMM
November 1st 2023Dr Rafael Fonesca reviews data from the TriMM-2 study presented at ASCO 2023 investigating combination talquetamab plus daratumumab for patients with relapsed/refractory multiple myeloma, highlighting a 78% response rate to talquetamab, but noting side effects like CRS and infections.
Watch
Relatlimab/Nivolumab in Metastatic Melanoma: Data From the RELATIVITY-047 Trial
November 1st 2023The RELATIVITY-047 trial evaluated relatlimab and nivolumab versus nivolumab alone in patients with metastatic melanoma, revealing improved progression-free survival, while PDL-1 status wasn't predictive of outcomes.
Watch
The Role of Lymphocyte-Activation Gene 3 (LAG-3) in Metastatic Melanoma
November 1st 2023Hussein Tawbi, MD, PhD, explains that LAG-3 is a marker of T-cell exhaustion, and combining LAG-3 inhibitors with PD-1 inhibitors can reverse this exhaustion, enhancing T-cell effectiveness and showing therapeutic benefits in patients with metastatic melanoma.
Watch
Available Treatment Options for Later Lines of Therapy in Patients With RRMM
November 1st 2023Rafael Fonseca, MD, emphasizes the considerations of selecting therapies targeting specific markers like BCMA and GPRC5D in patients with relapsed/refractory multiple myeloma, such as prior exposures, efficacy, and potential side effects.
Watch
Next Steps After New Frontline Therapy for dMMR Endometrial Cancer
October 27th 2023Matthew Powell, MD, discusses next steps and unmet needs following the phase 3 RUBY/ENGOT-EN6 study and the FDA approval of dostarlimab in combination with chemotherapy for the treatment of patients with mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer.
Watch
Optimizing Treatment Pathways in Non-Metastatic Castration-Resistant Prostate Cancer
October 27th 2023David Morris, MD, FACS, and Benjamin Garmezy, MD, discuss treatment options, including ARPIs like enzalutamide and darolutamide, in nmCRPC, emphasizing the importance of personalized approaches for patient quality of life and outcome improvement.
Watch
Safety and Efficacy of Mosunetuzumab in Elderly Patients With DLBCL
October 26th 2023Adam J. Olszewski, MD, discusses findings from a phase 1b/2 study which evaluated treatment with mosunetuzumab for the treatment of elderly/unfit patients who were previously untreated for their diffuse large B-cell lymphoma.
Watch
Brufsky Recaps PALOMA-2 Study of Palbociclib in Black Patients with aBC
October 25th 2023Adam Brufsky, MD, PhD, FACP, discusses background and next steps of the phase 3 PALOMA-2 study which evaluated palbociclib plus letrozole in patients that identified as Black or Hispanic with advanced breast cancer.
Watch